Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung
Lung
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
Lung
II
Ramirez, Robert
NCT04665739
SWOGTHOA021901
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Multiple Myeloma
N/A
Oluwole, Olalekan
NCT05346835
VICC-XDCTT24033
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic
Pancreatic
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Pancreatic
III
Cardin, Dana
NCT07621718
VICCGI26032
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Head/Neck
Head/Neck
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
Head/Neck
III
Choe, Jennifer
NCT07276399
VICCHN25044
STAR Trial (Siegel Transcatheter Aortic Valve Replacement in patients with symptomatic severe aortic stenosis)
Not Available
N/A
Goel, Kashish
VALV0019
Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-Cel) Out-of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
Leukemia
Leukemia
Leukemia
N/A
Oluwole, Olalekan
VICC-CTT25006
Safety and Functional Outcomes Following Laryngeal Transplantation
Head/Neck
Head/Neck
Head/Neck
N/A
Gelbard, Alexander
VICCHN2293
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Neuro-Oncology
Neuro-Oncology
Neuro-Oncology
Early I
Morone, Peter
VICCHN25072
A Window of Opportunity Study of Low-Dose Neoadjuvant Nivolumab in Head and Neck Squamous Cell Carcinoma (HNSCC)
Head/Neck
Head/Neck
Head/Neck
I
Rosenthal, Eben
VICCHN25078
Phase I Open-Label Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
Head/Neck
Head/Neck
Head/Neck
I
Rosenthal, Eben
VICCHNP26039
